Table 2.
Characteristics of the study population on the day of screening (n = 34).
| Characteristics | Mean ± SD | Range | Normal Values |
|---|---|---|---|
| Age, y | 50.11 ± 4.59 | 45–63 | - |
| BW, kg | 82.08 ± 12.13 | 57.6–106.4 | - |
| WC, cm | 93.94 ± 9.40 | 75–113 | <94 (b) |
| BMI, kg/m2 | 27.28 ± 3.28 | 20.0–33.5 | 20 to 25 (b) |
| PUL, b.p.m | 69.20 ±15.63 | 40–136 | 60–100 (c) |
| SBP, mm Hg | 122 ± 12.40 | 98–160 | 120 (b) |
| DBP, mm Hg | 80 ± 11.81 | 60–116 | 80 (b) |
| Triglycerides, mmol/L | 1.61 ± 0.93 | 0.66–4.55 | 1.7 (b) |
| Total cholesterol, mmol/L | 5.57 ± 0.58 | 3.72–8.04 | <4.0 (a) |
| HDL cholesterol, mmol/L | 1.38 ± 0.34 | 0.96–2.28 | ≥1.5 (a) |
| LDL cholesterol, mmol/L | 3.39 ± 0.89 | 1.75–5.51 | <2.6 (b) |
| GLU, mmol/L | 5.22 ± 0.55 | 4.06–6.42 | 4.9–5.3 (d) |
| Creatinine, µmol/L | 84.76 ± 19.08 | - | - |
| Urea, mg/dL | 34.03 ± 7.79 | - | - |
| Alanine Transaminase, U/L | 24.20 ± 7.83 | - | - |
| Aspartate. Transaminase, U/L | 21.97 ± 7.66 | - | - |
| Framingham risk score, % | 11.04 ± 5.73 | 3.30–25.30 | <10% (e) |
(a) American Heart Association, About Cholesterol. https://www.heart.org/en/health-topics/cholesterol/about-cholesterol. Accessed on 24 May 2020. (b) European Society of Cardiology, ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. https://www.escardio.org/Guidelines. Accessed on 24 May 2020. (c) American Heart Association, All About Heart Rate (Pulse). https://www.heart.org/en/health-topics/high-blood-pressure/the-facts-about-high-blood-pressure/all-about-heart-rate-pulse. Accessed on 24 May 2020. (d) World Health Organization, Global report on diabetes. World Health Organization, https://apps.who.int/iris/handle/10665/204871. Accessed on 24 May 2020. (e) Canadian Cardiovascular Society, Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. https://www.ccs.ca/en/guidelines/guidelines-library. Accessed on 24 May 2020.